Skip to main content
SpringerLink
Log in

New integrase inhibitor dolutegravir cost effective . . .

  • Meeting report
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Anti-Retroviral Analysis by Monte Carlo Individual Simulation model

References

  1. Despiegel N, et al. Cost-Effectiveness of Dolutegravir, a New Generation Integrase Inhibitor, in Hiv-1 Treatment Experienced Patients in France. 17th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes : (plus poster) abstr. PIN85, 8 Nov 2014. Available from: URL: http://www.ispor.org/RESEARCH_STUDY_DIGEST/list.asp?qs=39509.

  2. Hren R, et al. Cost-Effectiveness Analysis of Dolutegravir for Hiv Patients in Slovenia. 17th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes : abstr. PIN54, 8 Nov 2014. Available from: URL: http://www.ispor.org/RESEARCH_STUDY_DIGEST/list.asp?qs=39431.

  3. Stetka R, et al. Cost-Utility Analysis of Dolutegravir Compared to Raltegravir in Treatment Naive and Treatment Experienced Patients in Slovak Settings. 17th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes : abstr. PIN88, 8 Nov 2014. Available from: URL: http://www.ispor.org/RESEARCH_STUDY_DIGEST/list.asp?qs=39477.

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

New integrase inhibitor dolutegravir cost effective . . .. PharmacoEcon Outcomes News 717, 29 (2014). https://doi.org/10.1007/s40274-014-1754-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-014-1754-6

Search

Navigation